Trial Profile
The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome in Oocyte Donors.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetrorelix (Primary)
- Indications Ovarian hyperstimulation syndrome
- Focus Therapeutic Use
- 13 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 13 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Apr 2009 New trial record